About Neurocrine Biosciences
Neurocrine Biosciences is a leading pharmaceutical company that specializes in the discovery and development of innovative treatments for neurological and endocrine-based diseases and disorders. With a strong focus on research and development, Neurocrine has established itself as a pioneer in the field of neuroscience, delivering groundbreaking therapies that have transformed the lives of patients around the world.
Founded in 1992, Neurocrine has grown to become one of the most respected names in biopharmaceuticals. The company's R&D platform is built on a deep understanding of neurobiology, endocrinology, and related fields. This expertise allows Neurocrine to identify promising drug candidates early on in their development cycle, enabling them to move quickly from preclinical studies through clinical trials.
One area where Neurocrine has made significant strides is in treating movement disorders such as tardive dyskinesia (TD) and Parkinson's disease (PD). TD is a condition characterized by involuntary movements of the face, tongue, or limbs that can be caused by long-term use of certain medications. PD is a progressive disorder that affects movement control and can lead to tremors, stiffness, and difficulty with balance.
Neurocrine's flagship product for TD is Ingrezza® (valbenazine), which was approved by the FDA in 2017. Ingrezza® works by selectively inhibiting VMAT2 – a protein involved in regulating dopamine levels – thereby reducing abnormal movements associated with TD. Since its launch, Ingrezza® has been prescribed to thousands of patients across the US who have seen significant improvements in their symptoms.
In addition to Ingrezza®, Neurocrine also offers Ongentys® (opicapone) for PD patients who experience "off" episodes – periods when their medication wears off before their next dose. Ongentys® works by prolonging the effects of levodopa – an existing treatment for PD – thereby reducing "off" time and improving motor function.
Beyond these two products, Neurocrine has several other promising candidates under development across various therapeutic areas including rare pediatric diseases like congenital adrenal hyperplasia (CAH), which affects approximately one out every 10-15k newborns worldwide.
One key factor driving Neurocrine's success is its commitment to collaboration with other industry leaders. The company partners with academic institutions as well as biotech firms both domestically and internationally to leverage complementary expertise towards advancing new treatments faster than any single entity could do alone.
Another important aspect contributing towards this success story lies within its corporate culture - fostering innovation through diversity & inclusion initiatives aimed at attracting top talent from diverse backgrounds while promoting an inclusive work environment where everyone feels valued regardless if they are part-time employees or full-time staff members alike!
Overall it’s clear why so many people trust this innovative pharmaceutical company: they are dedicated not only towards developing cutting-edge treatments but also towards making sure those treatments reach those who need them most!